Fungi: Biology and Applications, Second Edition provides a comprehensive treatment of fungi, covering biochemistry, genetics and the medical and economic significance of these organisms at introductory level. With no prior knowledge of the subject assumed, the opening chapters offer a broad overview of the basics of fungal biology, in particular the physiology and genetics of fungi and also a new chapter on the application of genomics to fungi. Later chapters move on to include more detailed coverage of topics such as antibiotic and chemical commodities from fungi, new chapters on biotechnological use of fungal enzymes and fungal proteomics, and fungal diseases of humans, antifungal agents for use in human therapy and fungal pathogens of plants.
The ‘New Frontiers in Cancer Therapies: Focus on Transcription Factors, GTPases, Phosphatases and GPCRs, 2018-2030’ report provides a comprehensive study on the current market and therapeutic potential of the various pharmacological interventions designed against difficult-to-modulate cancer targets. It features an elaborate discussion on the future potential of this evolving domain, focusing on phosphatases, transcription factors, small GTPases (specifically Ras family) and undruggable G-protein coupled receptors (GPCRs). One of the key objectives of the study was to review and quantify the future opportunity for the ongoing product development programs of both small and big pharmaceutical firms. Amongst other elements, the report features: 1) A detailed assessment of the current market landscape of drugs being developed against various undruggable cancer targets, featuring information on the developer, phase of development (clinical, preclinical or discovery stage) of product candidate(s), information on type of molecule(s), biological target(s), mechanism of action, route of administration, and key therapeutic indication(s). 2) Elaborate profiles of key companies (selected based on pipeline strength); each profile features an overview of the company, details on it product portfolio, technology overview (wherever applicable), detailed information on advanced stage pipeline candidates (featuring a drug overview, clinical trial information and recent developments) and a comprehensive future outlook. 3) A section on emerging technologies and platforms that are aiding the development of therapies capable of targeting biological molecules which were previously considered as undruggable. 4) A detailed publication analysis on more than 70 research articles that have been published between January 2014 and March 2018, highlighting the key focus areas (biological targets and indications) of the ongoing research activity in this field. 5) An analysis of the partnerships that have been established in this domain in the recent past, covering R&D agreements, license agreements, clinical trial collaborations, mergers and acquisitions, and other relevant agreements. 6) An analysis of the investments made at various stages of development in companies that are focused in this area, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings. 7) A compilation of key insights derived based on various parameters; these include [A] a bull’s eye analysis highlighting the distribution of pipeline candidates in terms of phase of development, type of target family and type of molecule [B] a three-dimensional and five-dimensional spider web analyses of candidate therapeutics based on different parameters, namely number of publications, grants awarded to promote development, active clinical trials, current phase of development and the number of companies developing drugs against various undruggable targets, and [C] a world map representation, depicting the most active geographies in terms of the presence of companies developing drug candidates against difficult-to-modulate cancer targets.
Filling a gap in the literature, this guide provides expert recommendations and research on carcinoma of an unknown primary site (CUP). Covering the identification, diagnosis, and management of CUP with illustrative and reader-friendly clinical case examples, this reference helps physicians treat patients whose primary cancer site is difficult to l
Business and industry leaders are eager to find ways to spark the creative instinct in their work forces. The creation, implementation, and sustainability of new ideas is the lifeblood ensuring the growth and viability of any organization. Without continuing innovation, competitive advantage and global market share are endangered. Once-thriving organizations can find themselves unprepared for the future. This newly translated work examines the multi-layered environment of innovation by melding the thoughts of business management pundits like Peter Senge with the views of artist, politicians, and other non-traditional thinkers like Tao Ho, Peter Greenaway, and Wolfgang Rihm. These thought leaders share their insights and help us to understand the process of creativity and construction and the methods to move organizations forward in an ever-changing climate.
In his new book, Microsoft chairman and CEO Bill Gates discusses how technology can help run businesses better today and how it will transform the nature of business in the near future. Gates stresses the need for managers to view technology not as overhead but as a strategic asset, and offers detailed examples from Microsoft, GM, Dell, and many other successful companies. Companion Web site.
Discover how the application of novel multidisciplinary, integrative approaches and technologies are dramatically changing our understanding of the pathogenesis of infectious diseases and their treatments. Each article presents the state of the science, with a strong emphasis on new and emerging medical applications. The Encyclopedia of Infectious Diseases is organized into five parts. The first part examines current threats such as AIDS, malaria, SARS, and influenza. The second part addresses the evolution of pathogens and the relationship between human genetic diversity and the spread of infectious diseases. The next two parts highlight the most promising uses of molecular identification, vector control, satellite detection, surveillance, modeling, and high-throughput technologies. The final part explores specialized topics of current concern, including bioterrorism, world market and infectious diseases, and antibiotics for public health. Each article is written by one or more leading experts in the field of infectious diseases. These experts place all the latest findings from various disciplines in context, helping readers understand what is currently known, what the next generation of breakthroughs is likely to be, and where more research is needed. Several features facilitate research and deepen readers' understanding of infectious diseases: Illustrations help readers understand the pathogenesis and diagnosis of infectious diseases Lists of Web resources serve as a gateway to important research centers, government agencies, and other sources of information from around the world Information boxes highlight basic principles and specialized terminology International contributions offer perspectives on how infectious diseases are viewed by different cultures A special chapter discusses the representation of infectious diseases in art With its multidisciplinary approach, this encyclopedia helps point researchers in new promising directions and helps health professionals better understand the nature and treatment of infectious diseases.
